- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sk Biopharmaceuticals Co Ltd (326030)
Sk Biopharmaceuticals Co Ltd stock price live, this page displays KS 326030 stock exchange data. View the 326030 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sk Biopharmaceuticals Co Ltd real time stock price chart below.
What Is the Sk Biopharmaceuticals Co Ltd Stock Price Today?
The Sk Biopharmaceuticals Co Ltd stock price today is 99,600.
What Is the Stock Symbol for Sk Biopharmaceuticals Co Ltd?
The stock symbol for Sk Biopharmaceuticals Co Ltd is ""326030.""
What Stock Exchange Does Sk Biopharmaceuticals Co Ltd Trade On?
Sk Biopharmaceuticals Co Ltd is listed and trades on the Seoul stock exchange.
Is Sk Biopharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether Sk Biopharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 326030 quote. (ISIN: KR7326030004)
What Is the Sk Biopharmaceuticals Co Ltd Stock Price Today?
The Sk Biopharmaceuticals Co Ltd stock price today is 99,600.
What Is the Stock Symbol for Sk Biopharmaceuticals Co Ltd?
The stock symbol for Sk Biopharmaceuticals Co Ltd is ""326030.""
What Stock Exchange Does Sk Biopharmaceuticals Co Ltd Trade On?
Sk Biopharmaceuticals Co Ltd is listed and trades on the Seoul stock exchange.
Is Sk Biopharmaceuticals Co Ltd a Good Stock to Buy?
Determining whether Sk Biopharmaceuticals Co Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 326030 quote. (ISIN: KR7326030004)
Seoul
Currency in KRW
99,600
0(0.00%)
Closed·
Fair Value
An estimate of a Sk Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
99,400
101,400
52 wk Range
86,900
130,000
326030 Scorecard
Full Analysis
Impressive gross profit margins
326030 is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a Sk Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
99,400101,400
52 wk Range
86,900130,000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
326030 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Sk Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
141,733
Upside
+42.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Pharmaceuticals industry
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Sk Biopharmaceuticals Co Ltd Company Profile
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments; and research collaboration agreement with ProEn Therapeutics for accelerating expansion of oncology research and pipeline for radiopharmaceuticals. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Compare 326030 to Peers and Sector
Metrics to compare | 326030 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship326030PeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.1x | −2.8x | −0.5x | |
PEG Ratio | 0.02 | 0.04 | 0.00 | |
Price/Book | 13.8x | 1.1x | 2.6x | |
Price / LTM Sales | 13.5x | 0.9x | 3.3x | |
Upside (Analyst Target) | 50.6% | 54.9% | 43.4% | |
Fair Value Upside | Unlock | 12.9% | 7.1% | Unlock |
Analyst Ratings
13 Buy
2 Hold
1 Sell
Ratings:
16 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 141,733
(+42.30% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
390.33 / 314.45
Revenue / Forecast
176.30B / 167.06B
People Also Watch
FAQ
What Stock Exchange Does Sk Biopharma Trade On?
Sk Biopharma is listed and trades on the Seoul Stock Exchange stock exchange.
What Is the Stock Symbol for Sk Biopharma?
The stock symbol for Sk Biopharma is "326030."
What Is the Sk Biopharma Market Cap?
As of today, Sk Biopharma market cap is 7.80T.
What Is Sk Biopharma's Earnings Per Share (TTM)?
The Sk Biopharma EPS (TTM) is 3,207.77.
When Is the Next Sk Biopharma Earnings Date?
Sk Biopharma will release its next earnings report on 11 Nov 2025.
From a Technical Analysis Perspective, Is 326030 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Sk Biopharma Stock Split?
Sk Biopharma has split 0 times.
How Many Employees Does Sk Biopharma Have?
Sk Biopharma has 241 employees.
What is the current trading status of Sk Biopharma (326030)?
As of 08 Aug 2025, Sk Biopharma (326030) is trading at a price of 99,600.00, with a previous close of 99,600.00. The stock has fluctuated within a day range of 99,400.00 to 101,400.00, while its 52-week range spans from 86,900.00 to 130,000.00.
What Is Sk Biopharma (326030) Price Target According to Analysts?
The average 12-month price target for Sk Biopharma is KRW141733.33333, with a high estimate of KRW170000 and a low estimate of KRW71000. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +42.30% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.